



Universiteit
Leiden
The Netherlands

A systematic evaluation of the dosing regimens for approved targeted therapies and immune checkpoint inhibitors in metastatic renal cell carcinoma from a project OPTIMUS perspective

Tan, Z.; Völler, S.; Sancho-Araiz, A.; Knibbe, C.A.J.; Moes, D.J.A.R.

Citation

Tan, Z., Völler, S., Sancho-Araiz, A., Knibbe, C. A. J., & Moes, D. J. A. R. (2025). A systematic evaluation of the dosing regimens for approved targeted therapies and immune checkpoint inhibitors in metastatic renal cell carcinoma from a project OPTIMUS perspective. *The Journal Of Clinical Pharmacology*, 65(10), 1187-1207.
doi:10.1002/jcph.70035

Version: Publisher's Version
License: [Creative Commons CC BY-NC-ND 4.0 license](#)
Downloaded from: <https://hdl.handle.net/1887/4248390>

Note: To cite this publication please use the final published version (if applicable).

A Systematic Evaluation of the Dosing Regimens for Approved Targeted Therapies and Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma From a Project OPTIMUS Perspective

The Journal of Clinical Pharmacology
 2025, 65(10) 1187–1207
 © 2025 The Author(s). The Journal
 of Clinical Pharmacology published by
 Wiley Periodicals LLC on behalf of
 American College of Clinical Pharma-
 cology.
 DOI: 10.1002/jcph.70035

Zhiyuan Tan, MSc^{1,2} , Swantje Völler, PhD¹, Aymara Sancho-Araiz, PhD¹,
 Catherijne A. J. Knibbe, PharmD, PhD^{1,3} , and Dirk Jan A. R. Moes, PharmD, PhD²

Abstract

Targeted therapies and immune checkpoint inhibitors (ICIs) have significantly improved survival outcomes in metastatic renal cell carcinoma (mRCC) but are often associated with high rates of adverse events, leading to dose reductions or treatment discontinuation. The FDA's recent initiative, Project OPTIMUS, emphasizes the importance of optimizing dosing regimens in oncology clinical development, and moves beyond the conventional maximum tolerated dose approach. In this study, we aimed to review and redefine the approved dosing strategies for targeted therapies and ICIs in mRCC from the Project OPTIMUS perspective, including pazopanib, axitinib, cabozantinib, sunitinib, everolimus, and nivolumab. A comprehensive summary of FDA clinical pharmacology reviews and clinical studies performed in routine clinical practice was conducted, alongside model-informed simulations of pharmacokinetic profiles with approved and alternative regimens. Results demonstrated that actual tolerated doses in clinical practice were 46.1% to 86% lower than the approved dosages, with up to 75% of patients requiring dose adjustments. Model-informed simulations suggested that for most targeted therapies, a 14%–50% dose reduction maintained comparable efficacy while improving tolerability. For nivolumab, simulations confirmed adequate drug exposure with the approved flat dose regimens, without an increase of adverse effects. In conclusion, we identified optimized dosing regimens that could improve drug tolerability while maintaining efficacy for approved targeted therapies and ICIs in mRCC. We suggest that these optimized dosing regimens should be considered for use in clinical practice and that the optimal exposure range should be included in drug labels to support pharmacokinetically guided dose individualization in clinical practice.

Keywords

axitinib, cabozantinib, dose optimization, dose reduction, dose selection, everolimus, nivolumab, pazopanib, sunitinib

Introduction

Targeted Therapies and Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Metastatic renal cell carcinoma (mRCC) is the most common tumor of the urological system with poor prognosis.¹ Over the last decades, the treatment of mRCC has improved considerably with targeted therapies that block vascular endothelial growth factor (VEGF) or mechanistic target of rapamycin (mTOR) pathways. These therapies significantly improved objective response rates (ORR) and/or median progression-free survival (PFS).² Since 2005, FDA and EMA approved several tyrosine kinase inhibitors (TKIs) such as sunitinib, pazopanib, axitinib, cabozantinib, and the mTOR inhibitors everolimus and temsirolimus.³ Despite superior outcomes, tumors treated with small molecules are prone to develop drug resistance.⁴ Therefore, the treatment landscape is advancing toward novel immune checkpoint inhibitors (ICIs)-based strategies, either monotherapies or in combination.⁵ These therapies, which target the interaction between immune cells and tumor cells, have shown success in improving

mRCC outcomes,⁶ with more durable efficacy compared to small molecules.⁷

¹Division of Systems Pharmacology and Pharmacy, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

²Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands

³Department of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, The Netherlands

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Submitted for publication 10 February 2025; accepted 2 April 2025.

Corresponding Author:

Dirk Jan A. R. Moes, PharmD, PhD, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
 Email: D.J.A.R.Moes@lumc.nl

Catherijne A. J. Knibbe is Fellow of the American College of Clinical Pharmacology.

[Correction added on May 15, 2025, after first online publication: A minor change was made to the abstract and a new reference was added.]

Current Problem in Clinical Development

The maximum tolerated dose (MTD), which is defined as the highest dose that does not cause dose-limiting toxicity (DLT, the same grade 3 or 4 adverse event [AE] in three or more patients⁸), has been the gold standard for dose selection in oncology dose-finding trials and is often adopted as the recommended Phase II dose (RP2D).⁹ However, targeted therapies demonstrate a different dose-response relationship compared to classic cytotoxic chemotherapy. More specifically, doses below the MTD may have similar efficacy to the MTD but may be associated with less toxicity.¹⁰ This idea is supported by high rates of dose reduction in routine clinical practice for many well-established targeted agents like cabozantinib and everolimus in mRCC at similar efficacy^{11, 12} reflecting potentially inadequate dose selection prior to the registration trial.¹³ In addition, the traditional MTD paradigm often does not adequately evaluate other data, such as low-grade symptomatic toxicities (i.e., grade 1-2), dosage modifications, dose- and exposure-response relationships.¹⁰ An even larger inconsistency of exposure-response and exposure-toxicity relationship is observed in ICIs. For nivolumab, a flat exposure-response relationship was well established and has led to label change from weight-based dosing to alternative flat dosing strategy.¹⁴ It has even been shown that nivolumab 20 mg versus placebo every 3 weeks (Q3w) leads to improved 1-year overall survival (OS) in head and neck cancer,¹⁵ with 20 mg being considerably lower than the standard dose (3 mg/kg q2w or 240 mg q2w).

FDA Project OPTIMUS. The emerging evidence that targeted therapies are poorly tolerated at the approved recommended MTD-based dosage was also noted by FDA.¹⁰ FDA reviewed the dose-related post-marketing requirements¹⁶ between 2010 and 2015 and found 33.3% new molecular entities (NMEs) had dose-related post-marketing requirements. As a result, in 2021 FDA Project OPTIMUS¹⁰ was initiated, aiming to reform and improve dose optimization and selection in oncology drug development.¹⁷ The main recommendations are to collect and interpret all available clinical pharmacokinetic, pharmacodynamic, and pharmacogenomic data to identify the optimal dose rather than taking the MTD, as well as identifying a target dosage range early and then further evaluating several dosages.¹⁰ Another focus is to improve tolerability, which enables patients to remain on the effective targeted therapies or ICI treatment for longer period and results in reduced medical expenses.

In this report on six approved targeted therapies and ICI in mRCC (i.e., pazopanib, axitinib, cabozantinib, sunitinib, everolimus, and nivolumab), we reviewed the approved dosages together with the dose-finding

strategy, followed by an evaluation of routine clinical practice studies on the actual tolerated and effective doses and exposures observed in clinical practice. Finally, published pharmacokinetic (PK) models were assessed and selected for model-informed simulations to evaluate dosing from the perspective of optimal target achievement in the post-marketing context.

Methods

Overall Methods

For five targeted therapies (i.e., pazopanib, axitinib, cabozantinib, sunitinib, and everolimus) and one ICI product (i.e., nivolumab) approved for mRCC, we first retrieved the approved dose and dose-finding strategy reported in the FDA clinical pharmacology review dossier. Second, routine clinical practice studies on dose reduction and alternative dose regimen information are presented and qualitatively summarized. Finally, published PK models of these targeted and ICIs are summarized and one of the models of each drug is selected for generating model-based optimal dose regimen that achieves the desired target exposure.

Literature Search and PK Model Selection

The literature search is divided into three parts. First, FDA clinical pharmacology reviews of each drug were retrieved from FDA drug approval database (<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>).

Second, routine clinical practice studies including dose reduction or interruption information and studies that compared the approved dose with alternative regimens were retrieved. The approved dose, dose reduction rate, and dose intensity are summarized in Table 1.

Third, published population PK modeling studies and reviews on exposure targets are used to perform model-informed simulations, summarized in Table 2. The dose regimens selected for the simulations are listed in Table S1. Simulation regimens were chosen based on factors such as dose reduction rate in routine clinical practice, the available dose strengths on the market, and other possible doses that can result in achieving the exposure target. Detailed search terms and retrieved PK models are provided in Supplemental Information. For drugs with more than one PK model, the following priorities are applied to select the preferred model for simulations: (1) The model derived from registration files, with external validation using routine clinical data (if available), is the preferred option; (2) If the preferred model is not available, the registration file model should be used; (3) If neither of the above models is available, a model based solely on routine clinical data should be considered; (4) Ideally, a model based on a larger population and without inter-occasion variability should be selected. Models that do not clearly define the occasions will be excluded; (5) Information

Table 1. Results on Dose Reduction and Dose Intensity in Routine Clinical Practice Studies

Study	Labeled Dose	Number of Patients	Starting Dose in the Studies	Dose Reduction Rate [% of Patients] [*]	Dose Intensity [Mean Dose [§]] OR Relative Dose Intensity ^{&} (%)
Pazopanib	800 mg QD				
Shah et al ¹⁸		19	-	40%	-
Johnston et al ¹⁹		-	800 mg QD	60%	78%
Gaillard et al ²⁰		18	800 mg QD (60% of patients [†])	-	672 mg QD
Masini et al ²¹		279	800 mg QD	36%-66%	-
Axitinib	5 mg BID				
Johnston et al ¹⁹		-	5 mg BID	22%	95%
Gaillard et al ²⁰		12	5 mg BID (60% of patients [†])	-	8.6 mg per day (4.3 mg BID)
Cabozantinib	60 mg QD				
Albiges et al ²²		410	60 mg QD (71% of patients [†])	57%	-
Krens et al ²³		59	60 mg QD (46% of patients [†])	58%	-
Campbell et al ²⁴		30	-	60%	-
Gan et al ²⁵		413	-	50%	-
Martini et al ²⁶		87	60 mg QD	68%	-
Prisciandaro ²⁷		17	60 mg QD	47%	-
McElwee et al ²⁸		35	-	-	33 mg QD
Sunitinib	50 mg 4/2				
Gaillard et al ²⁰		12	50 mg QD 4/2 (60% of patients [†])	-	34 mg QD
Porta et al ²⁹		85	50 mg QD 4/2	30%	-
Park et al ³⁰		270	50 mg QD 4/2	54%	-
Miyake et al ³¹		110	50 mg QD 4/2	93%	63%
Abd Ghafar et al ³²		51	50 mg QD 4/2	61%	-
Noize et al ³³		302	50 mg QD 4/2 (83.4% of patients [†])	65%	-
Everolimus	10 mg QD				
Nozawa et al ³⁴		180	10 mg QD	40%	-

-, no information reported by the study; 4/2, 4 weeks on and 2 weeks off treatment; BID, twice daily; QD, once daily.

^{*}The percentage of patients who experienced dose reduction during follow-up.

[§]The mean dose was calculated by dividing the sum of overall daily doses by number of days on therapy for all patients as reported by the studies.

[&]Relative dose intensity was calculated by dividing the actual daily dose (the mean of the sum of all daily doses divided by the number of days on therapy) by the starting dose as reported by the studies.

[†]With the remaining patients starting at lower dosages.

on individuals included in the model who had concomitant therapy (potential drug-drug interaction and combination therapy) is excluded. Parameter estimates and covariates information of the selected models are provided in the Supplemental Information.

Model-Informed Simulations to Guide Optimal Dosing Regimens

The approved and alternative dose regimens retrieved as described in “Literature Search and PK Model Selection” are used for model-informed simulations. To this end, 1000 virtual adult patients per regimen are generated by the copula covariate simulator (CoCoSim) web application (<https://cocosim.lacdr.leidenuniv.nl/>) based on the covariates in National Health and Nutrition Examination Survey dataset.⁴⁰ If the model includes a covariate that cannot be generated by CoCoSim,

for example the prognosis score, random generation and assignment using the mean and standard deviation statistics from the original PK model publication will be used. Previously published reviews on exposure targets of these therapies are utilized directly as simulation exposure targets.^{35–37} If multiple targets have been reported for one drug, the evidence evaluation hierarchy was applied: (1) the evidence from systematic review/meta-analysis; (2) the evidence from prospective studies; (3) the evidence from retrospective studies used in model-based exposure-response analysis; (4) if none of the above evidence could be retrieved, then no solid target could be used for simulation. In addition, percentage of target attainment (PTA) at steady state is summarized (the percentage of patients achieving the therapeutic target at steady state in the 1000 virtual patients). All simulations were performed in NONMEM

Table 2. Recommended Starting Dose Based on Labeled Dose, Routine Clinical Practice Studies, and Model-Informed Results

Drug	Labeled Dose	Dose in Routine Clinical Practice*	Efficacy Target Concentration ^[REF]	Toxicity Target Concentration ^[REF]	Model-Informed Dose [§]	Conclusions and Recommended Starting Dose [‡]
Pazopanib	800 mg QD	600 mg QD	$C_{min,ss} \geq 20.5 \text{ ng/mL}$ ^{35,36}	$C_{min,ss} < 46 \text{ or } 50 \text{ ng/mL}$ ^{35,36}	600 mg QD	600 mg QD
Axitinib	5 mg BID	4 mg BID	$C_{min,ss} > 1.76 \text{ ng/mL}$ ^{35,37}	$C_{max,ss} > 40.2 \text{ ng/mL}$ ^{35,37}	5 mg BID	5 mg BID
Cabozantinib	60 mg QD	40 mg QD	$C_{min,ss} > 336 \text{ ng/mL}$ ³⁸	$C_{min,ss} < 750 \text{ ng/mL}$ ³⁸	60 mg QD * 2 days + 1 day skip	60 mg QD * 2 days + 1 day skip
Sunitinib [#]	50 mg QD 4/2	37.5 mg QD	$C_{min,ss} \geq 50 \text{ ng/mL}$ ³⁵	$C_{min,ss} < 100 \text{ ng/mL}$ ³⁵	40 mg QD	40 mg QD
Everolimus	10 mg QD	-	$C_{min,ss} > 10 \text{ ng/mL}$ ³⁵	$C_{min,ss} \leq 26.3 \text{ ng/mL}$ ³⁵	50 mg QD 2/1	50 mg QD 2/1
Nivolumab	3 mg/kg	-	$C_{min,ss} > 2.5 \text{ mg/L}$ ³⁹	/	5 mg QD	37.5 mg QD
	240 mg Q2W				3 mg/kg	5 mg QD
	480 mg Q4W				240 mg Q2W	3 mg/kg
					480 mg Q4W	240 mg Q2W
					360 mg Q3W	480 mg Q4W
						360 mg Q3W

-, no solid evidence from routine clinical practice studies; /, no solid relationship available of nivolumab exposure with toxicities; 4/2, 4 weeks on and 2 weeks off treatment; 2/1, 2 weeks on and 1 week off treatment; BID, twice daily; $C_{max,ss}$, maximum concentration at steady state; $C_{min,ss}$, trough concentration at steady state; Q2W, once every 2 weeks; Q3W, once every 3 weeks; Q4W, once every 4 weeks; QD, once daily, [REF], the references for the efficacy and toxicity exposure targets.

*The information of this column was taken from Table 1 and rounded to the nearest tablet/pill/vial strength.

§ Derived from the model-informed simulations as described under paragraphs 3.3, 4.3, 5.3, 6.3, 7.3, using the selected PK models and exposure targets.

‡ The conclusions and recommended starting dose regimens are based on the previous columns and expert opinion if there is discrepancy between dose in routine clinical practice and model-informed dose.

Sunitinib exposure metric is the composite $C_{min,ss}$ of both parent drug and main metabolite (sunitinib and SU12662).

7.4.4. Further statistical comparison and visualization of exposure over time was performed in R.

Pazopanib

Approved Dose and Dose-Finding Strategy

Pazopanib was approved for mRCC in 2009 by the FDA.⁴¹ Its primary mechanism of action can be described through its anti-angiogenic properties via inhibition of the intracellular tyrosine kinase of VEGF receptor (VEGFR).⁴² The recommended dose is 800 mg orally once daily (QD) without food. Pazopanib has a bioavailability range of 14% to 39% and is highly bound to protein (>98.8%).⁴³ It is primarily metabolized by CYP3A4, therefore 200 mg QD is recommended for moderate hepatic impairment and its use in severe hepatic impairment should be avoided.⁴¹

As for the dose-finding strategy of pazopanib, a Phase I dose-escalation study involving 63 patients was performed where doses ranging from 50 to 2000 mg were evaluated in the dose-escalation phase and 300 mg BID, 400 mg BID, and 800 mg QD were evaluated in the dose-expansion phase. Exposure seemed to increase proportionally with doses between 50 and 400 mg even though variability was high,⁴⁴ and dose proportionality beyond 400 mg was marginal. Mean trough concentrations at steady state ($C_{min,ss}$) on day 22 were similar for four dosing regimens (800 mg QD, 1000 mg QD, 300 mg BID, and 400 mg BID). Despite these findings, no MTD was reached during this study. Figure 1a summarizes the number of responders for the different dose levels, showing that pazopanib doses ≥ 400 mg result in clinical response. Regarding safety, DLTs were identified in 4 out of 63 patients, occurring at 50 mg (2/9), 800 mg (1/3), and 2000 mg QD (1/3). These data led to the selection of 800 mg QD as the dose for registration trials.⁴⁵

Subsequently, exposure-response analysis conducted by FDA combined available data across trials⁴⁶ and stratified the patients into quartiles based on the $C_{min,ss}$ for survival analysis. The survival curves of patients with different trough concentration-quartile groups overlapped at several points, indicating an absence of an exposure-response relation for efficacy at the registered dose. In contrast, logistic regression analysis using data from the registration trial⁴⁵ demonstrated that the probability of grade 3+ ALT elevations increased with increased pazopanib exposure (Figure 1b), revealing a significant exposure-toxicity relationship.

Clinical Routine Practice Studies of Dose Reduction and Alternative Regimens

In clinical practice, dose reduction rate and related outcomes have been reported in several published studies (Table 1), ranged from 40%¹⁸ to 60%^{19, 20} in different studies, starting with 800 mg QD. Given the 200 mg per

tablet formulation, alternative dosing strategies such as 600 mg QD and 400 mg QD have emerged as potential starting doses.

Evidence from retrospective studies highlights the potential benefits of dose adjustments. A study⁵¹ involving 179 patients with mRCC, almost exclusively receiving pazopanib as first-line treatment, found a statistically significant improvement in PFS and OS for patients who underwent dose reductions ($P < 0.0001$ for both PFS and OS), temporary interruption ($P < .0001$ for both PFS and OS) and schedule modifications ($P = .007$ for PFS and $P = .012$ for OS) compared to those who maintained the original dosing schedule.

Further support for dose reduction comes from a larger study by Lacovelli et al,⁵² including 591 mRCC patients receiving pazopanib. Of these, 45.7% (270 out of 591 patients) required a dose reduction due to toxicity. Interestingly, patients who reduced their dose, achieved a median OS of 49.4 months, significantly longer than the 24.0 months observed in those who continued the standard dose (hazard ratio = 1.80, $P = .001$).

However, not all studies have demonstrated consistent outcomes. Grassi et al⁵³ retrospectively compared the outcome of 69 mRCC patients treated with pazopanib, dividing them into three groups: group 1 included 34 patients who started with 800 mg QD and did not have a dose reduction, group 2 included 19 patients who started with 800 mg QD but reduced their dose to 400 or 600 mg QD due to toxicity, and group 3 included 16 patients who started with 400 or 600 mg QD due to poor prognosis. ORRs were 44%, 11%, and 19% in the three groups, respectively. Discontinuation rates due to progressive disease (PD) were higher in groups 2 and 3 (42% and 44%, respectively) than group 1 (28%). However, the authors noted that these differences might reflect the worse prognosis of groups 2 and 3, and therefore the results should be interpreted with caution.

Model-Informed Dose Based on Published Exposure Target and PK Model

The current exposure target of pazopanib, specifically the $C_{min,ss}$ target, ranges between 20.5 and 46–50 mg/L (Table 2). The upper threshold aimed at minimizing overall CTCAE ≥ 3 toxicity.³⁷

In total, four pazopanib PK models^{54–56} were identified, and based on the model selection workflow as described in Methods section, we selected the model developed by our own group for simulations.⁵⁷ This model is based on routine clinical practice data while utilizing the model structure based on the large clinical trial datasets for marketing authorization, and contained no covariates. Considering the current tablets available on the market (200 mg/tablet), simulations were performed




Figure 1. Dose-exposure, dose/exposure-response, or exposure-toxicity relationship of the investigated targeted therapies and ICI in clinical trials. (a) Pazopanib dose-response relationship based on Phase I trial data.⁴⁶ The plot represents the proportion of responders (best response - complete/partial response or stable disease of any duration) versus pazopanib dose. For this plot, a subset of patients who received once daily pazopanib dose were selected; (b) Pazopanib exposure-severe liver toxicity relationship based on registration study; (c) Axitinib dose-exposure relationship based on Phase I trial⁴⁷; (d) Axitinib exposure-severe hypertension relationship based on registration trial⁴⁷; (e) Cabozantinib exposure-response relationship in registration study⁴⁸; (f) Cabozantinib exposure-severe hand-foot syndrome relationship in registration study⁴⁸; (g) Sunitinib exposure-response relationship split by AUC in registration study.⁴⁹ Red curve indicates the group of high sunitinib AUC_{tot} (AUC_{tot} > 1900 ng·h/mL) and blue curve indicates the group of low sunitinib AUC_{tot} (AUC_{tot} < 1900 ng·h/mL); (h) Sunitinib exposure-grade 3/4 neutropenia relationship in registration study⁴⁹; (i) Everolimus exposure-efficacy relationship divided by placebo and different C_{min,ss} groups.⁵⁰ The red curve indicates the placebo group and the blue curves indicate different C_{min,ss} quantile group; (j) Everolimus exposure-anemia relationship.⁵⁰ All sub-figures were replotted from the FDA Clinical Pharmacology and Biopharmaceutics Review of pazopanib,⁴⁶ axitinib,⁴⁷ cabozantinib,⁴⁸ sunitinib,⁴⁹ and everolimus.⁵⁰




Figure 2. Model-informed pazopanib dose exploration using the model of Tan et al. Blue dashed line indicates the efficacy target $C_{\min,ss} > 20.5$ mg/L. Red dashed line indicates the toxicity target $C_{\min,ss} < 46$ mg/L. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

at three starting dose levels: 800, 600, and 400 mg QD. For the three simulated dosing regimens (Figure 2), although dose-related exposure differences are still discernible, there is an overlapping of the 90% prediction intervals (PI) due to high variability. While a starting dose of 400 mg QD may not result in the desired target for some patients, both 600 mg and 800 mg QD meet the $C_{\min,ss}$ target of 20.5 mg/L. In addition, 600 mg QD could also meet the safety threshold of 46 mg/L. The therapeutic target achievement calculation results (Table S1) show that 600 mg QD results in a similar efficacy target attainment (75.6%) compared to 800 mg (85.9%), but with a lower incidence of toxicity (5.8% vs 16.1%).

Axitinib

Approved Dose and Dose-Finding Strategy

Axitinib was approved by the FDA in 2012 for mRCC in patients who had failed one prior systemic therapy.⁵⁸ Its mechanism of action is to inhibit VEGFR-1, 2, and 3 selectively.⁵⁹ The approved labelled oral dose is 5 mg twice daily (BID), with dose titration up to 7 mg BID and further to 10 mg BID, based on tolerability. The PK is dose proportional within the clinical dose range.⁶⁰ Following oral administration, axitinib is absorbed rapidly, with maximum observed plasma concentrations ($C_{\max}$) reached within 4 h. Its effective plasma half-life ranges between 2.5 and 6.1 h after a single oral dose.⁴⁷ Axitinib has a mean absolute bioavailability of 58 % and has >99 % protein binding.⁶⁰

Dose selection was based on MTD criteria in a Phase I PK and tolerability study that assessed various doses, including 10 mg QD, 15 mg QD, 5 mg BID, 10 mg

BID, 20 mg BID, and 30 mg BID. Substantial inter-individual variability was observed, with a coefficient of variation of 60% in area under the curve (AUC) following an axitinib dose of 5 mg BID.⁴⁷

The dose-exposure relationship was generally linear (Figure 1c) within the studied range based on the Phase I trial.⁴⁷ Exposure-response studies pooled data from three Phase II trials (178 patients) and the pivotal Phase III trial (55 patients). Patients tolerating the initial 5mg BID dose with upward titrations showed lower axitinib exposures at the starting dose, suggesting potential benefits from higher initial doses.⁴⁷ However, insufficient data from the Phase III trial and other public databases prevented establishing a conclusive exposure-response relationship for PFS.⁴⁷ In the exposure-toxicity evaluation, the logistic regression model demonstrated an exposure-dependent increase in hypertension (Figure 1d), proteinuria, fatigue, and diarrhea.⁴⁷

Clinical Routine Practice Studies of Dose Reduction and Alternative Regimens

Several studies have evaluated axitinib tolerance in routine clinical practice setting (Table 1). Yasuoka et al⁶¹ retrospectively collected data from 17 mRCC patients treated with axitinib at 5 mg of BID (10 mg/day) following first-line nivolumab therapy. All patients experienced AEs, with nine patients (52.9%) requiring dose reduction or treatment interruption. Similarly, another retrospective study,²⁰ which included 12 axitinib-treated patients, reported a median relative daily dose of 8.6 ± 2.6 mg/day with 50% of patients requiring dose reductions due to toxicity.




Figure 3. Model-informed axitinib dose exploration using Rini model.⁶⁶ Blue dashed line indicates the efficacy target $C_{\min,ss} > 1.76$ ng/mL. Red dashed line indicates the toxicity target $C_{\max,ss} < 40.2$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

In contrast, a larger cohort study¹⁹ reported a lower dose reduction rate of 22%, despite a similar median starting dose of 5 mg BID. Notably, most patients in this cohort (63%) received axitinib as part of combination therapy, potentially influencing the lower rate of dose adjustment.

Model-Informed Dose Based on Published Exposure Target and PK Model

Axitinib has a reported efficacy target of $C_{\min,ss} > 1.76$ ng/mL at 1–3 months after start of treatment from an exposure-response analysis based on clinical practice data⁶² (Table 2). The cumulative incidence of DLT was significantly higher in patients with $C_{\max,ss} > 40.2$ ng/mL⁶³ which was selected as toxicity target (Table 2).

Three axitinib PK models were retrieved,^{64–66} all with the same model structure. The model published by Rini et al⁶⁶ (Rini model) based on 17 clinical trials was selected for simulation due to the solid design, large sample size, and robust parameter estimates. The simulated doses included 3, 5, 7, and 10 mg BID that were used as dose titration/de-escalation in drug approval. Figure 3 depicts simulated PK profiles for the explored regimens. Numerical results for these simulations can be found in Table S1. The approved starting dose of 5 mg BID results in achievement of $C_{\min,ss}$ target in 86.8% of the patients which is in line with the routine clinical practice summary that 5% of the 5 mg BID

group would be beyond the target that may need dose de-escalation to 3 mg BID (Table S1).

Cabozantinib

Approved Dose and Dose-Finding Strategy

Cabozantinib was approved by the FDA in 2012 for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy. This multi-kinase TKI exerts its effects by inhibiting several key pathways involved in cancer progression.⁶⁷ Specifically, cabozantinib targets the MET proto-oncogene (MET) and VEGFR2, reducing angiogenesis and diminishing drug resistance and metastasis.⁶⁸ The labeled dose is 60 mg QD fasted⁶⁹ since high-fat diet increases its bioavailability on average by 57%.⁷⁰ Available tablet strengths include 60, 40, and 20 mg. Following oral administration, cabozantinib showed dose-proportional increases in mean plasma concentrations. It has an exceptionally long terminal half-life ($t_{1/2}$) of approximately 99 h, which supports once-daily dosing.

The dose selection was based on a Phase I study that investigated 20, 40, 60, and 140 mg QD, with 60 mg QD chosen as starting dose. An exposure-response study⁷¹ was performed using data from a Phase III METEOR study,⁷² where all patients received an initial dose of 60 mg QD. The analysis used a previously developed PK model⁷³ (PK model developed using healthy volunteers and patients with different tumor types) to predict

average steady-state concentrations ($C_{avg,ss}$) for 60 mg QD (1125 ng/mL), 40 mg QD (750 ng/mL), and 20 mg QD (375 ng/mL) doses. Simulations showed hazard ratios (HR) for disease progression or death of 1.10 (40mg) and 1.39 (20mg) compared with 1125 ng/mL group. Based on these results, while 60 mg QD was considered superior for efficacy, the Kaplan-Meier plot (Figure 1e) showed no significant survival differences between the exposure quartiles, suggesting inconclusive exposure-response relationship for PFS.⁷¹ Regarding safety, an exposure-response analysis revealed a dose-dependent increase in the risk of severe hand-foot syndrome (Figure 1f). The predicted HR 2.21 (60 vs 20 mg) and 1.49 (60 vs 40 mg). Overall, while 60 mg QD dose showed better efficacy than lower doses it may not be optimal due to safety concerns and AE risks.⁴⁸

Clinical Routine Practice Studies of Dose Reduction and Alternative Regimens

Martini et al²⁶ included 87 mRCC patients, 33% of whom received cabozantinib as first-line therapy. Among the cohort, 68% required a dose reduction from 60 mg or started the treatment at a reduced dose without escalation. Patients receiving reduced doses were more likely to have ≥ 3 distant metastatic sites and ≥ 2 prior lines of systemic therapy compared to full dose patients. Regression analysis revealed a trend toward shorter OS (HR: 1.78, $P = .095$), shorter PFS (HR: 1.50, $P = .107$), and lower chance of objective response (HR: 0.42, $P = .149$) in reduced dose patients. However, these trends did not remain significant in multivariable analysis (OS HR: 1.20, $P = .636$; PFS HR: 1.23, $P = .4662$).

Recently, a retrospective analysis⁷⁴ of 71 mRCC patients revealed that 39.1% of patients were offered an alternative dose regimen due to intolerance. These alternative schedules included intermittent dosing patterns such as 14 days on treatment followed by 7 days off treatment, or 7 days on treatment followed by 4 days off treatment. Starting doses were 60 and 40 mg in 50.7% and 32.4% of patients, respectively. Compared to continuous dosing, alternative treatment schedules were associated with longer PFS (12.2 vs 6.1 months, $P = .014$). Toxicities were similar between the groups, with all-grade AE reported in 96.9% of patients on continuous dosing and 96% on alternative schedules. However, grade 3 or higher AEs occurred more often in the continuous dosing group (84.4% vs 75%).

Additional studies have provided additional information regarding routine clinical practice tolerance of cabozantinib^{22–25, 27, 28, 75–77} (Table 1). High rates of dose reduction were consistently observed across multiple retrospective analyses. For instance, a study with 410 mRCC patients²² revealed that 57.0% of patients had a dose reduction, and 15.6% had an alternative

dose schedule, with a median average daily dose of 40 mg. Similarly, another study involving 413 patients²⁵ reported that approximately 50% of patients required dose reductions with an average relative dose of 33 mg (55.4% of the standard 60 mg dose). Dose reductions were associated with significantly longer time to treatment failure (TTF) and overall survival (OS) compared to those who did not require dose reductions (adjusted hazard ratios of 0.37, $P < .01$ for TTF and 0.46, $P = .04$ for OS).

Consistent findings were reported by Krens et al,²³ who observed a dose reduction rate of 58% and improved PFS for patients with dose reductions (65 vs 31 weeks, $P = .001$). Smaller studies also reported dose reduction rate ranging from 47% to 57%, showing that dose reductions are common and potentially beneficial in routine clinical practice settings.^{24, 27, 76}

Model-Informed Dose Based on Published Exposure Target and PK Model

Cabozantinib is suggested to have a therapeutic window³⁸ of $C_{min,ss} > 336$ ng/mL and $C_{min,ss} < 750$ ng/mL (Table 2), though these values have not yet been widely accepted. Several PK models developed with clinical trial data were retrieved.^{71, 73, 78, 79} The model adapted from the FDA registration file⁷⁸ for mRCC with routine clinical data (Tan model⁷⁰) was selected which did not include other tumor types and could better reflect the routine clinical setting. Results of simulated regimens with this model⁷⁰ are shown in Figure 4. The approved 60 mg QD starting dose exhibited substantially higher exposure than desired $C_{min,ss}$ target for both efficacy and safety while an alternative dose of 40 mg QD seems to maintain the balance between efficacy and safety in a better way. Taking into consideration the flat pricing strategy of cabozantinib for all available strengths (the 20, 40, and 60 mg tablets share exactly the same price), another starting dose of 60 mg QD given 2 days and skip 1 day could not only offer the same target achievement compared to the 60 mg QD continuous dose (35.6% vs 20.8%, Table S1) but also save drug expenses.⁷⁰

Sunitinib

Approved Dose and Dose-Finding Strategy

Sunitinib was among the first approved TKIs by the FDA in 2006 indicated for all mRCC patients. Sunitinib was identified as a potent inhibitor of VEGFR-1, VEGFR-2 FLT3, KIT, and PDGFR with antitumor and anti-angiogenic activities.⁸⁰ The approved oral dose is 50 mg QD with 4 weeks on and 2 weeks off (4/2).⁸¹ It is slowly absorbed, reaching peak concentrations (T_{max}) between 6 and 12 h, regardless of food intake. After absorption, sunitinib undergoes CYP3A4 mediated de-ethylation metabolism, producing SU012662, an active




Figure 4. Model-informed cabozantinib dose exploration using model of Tan et al.⁷⁰ Blue dashed line indicates the efficacy target $C_{min,ss} > 336$ ng/mL. Red dashed line indicates the safety target $C_{min,ss} \leq 750$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

and equipotent metabolite. This metabolite contributes approximately 23%-37% of the total AUC of the parent drug. The elimination half-life ($t_{1/2}$) of the parent compound and the metabolite are prolonged, with values of 40-60 h and 80-100 h, respectively.⁴⁹ The PK models have shown significant inter-individual variability, with estimated coefficient of variation (%) of 21-71% for CL and 25-60% for AUC.⁴⁹

Dose-finding studies for sunitinib began with a Phase I study in solid tumors, testing doses from 50 mg once every other day (QOD) to 150 mg QD.⁸² Based on dose linearity and DLT observed at the next dose level of 75 mg QD 4/2, 50 mg QD was chosen for further development.⁴⁹

Following Phase I, two single-arm studies were conducted to evaluate the PK and PD relationship in mRCC patients. Exposure, measured as the combined steady-state AUC of sunitinib and SU012662 (AUC_{tot}) was evaluated in relation to both the efficacy and safety endpoint. For efficacy, time to tumor progression was used as the primary endpoint. Non-parametric Kaplan–Meier curves and parametric time-to-event modeling showed no clear exposure–response relationship for either AUC_{tot} or parent AUC alone. However, when Kaplan–Meier plots were stratified by exposure (low AUC [$AUC_{tot} < 1900$ ng•h/mL] and high AUC [$AUC_{tot} > 1900$ ng•h/mL]), the high AUC group appeared to show slightly longer time to progression

and improved OS according to Figure 1g.⁴⁹ For safety, logistic regression revealed significant exposure–toxicity relationships across multiple endpoints, including grade 3/4 neutropenia (Figure 1h).⁴⁹ In further Phase III registration trial, only 50 mg QD 4/2 was used. Dose reduction was seen in 32% of the patients,⁸³ and despite the relative high response rates across the exposure levels, there was no apparent exposure–partial response observed at 50 mg QD 4/2.⁴⁹

Clinical Routine Practice Studies of Dose Reduction and Alternative Regimens

In clinical practice, a substantial number of studies have evaluated alternative regimens for sunitinib^{31–33, 52, 84–116} (detailed information is summarized in Supplemental Information 2). Among these, 23 studies^{52, 94–116} compared outcomes between the standard regimen and various alternative regimens. The most commonly studied alternative dose was 50 mg 2 weeks on and 1 week off (2/1) as alternative regimen (50 mg 2/1), which provides the same overall dose as 50 mg 4/2. A meta-analysis has summarized these studies and compared the efficacy and safety of the 50 mg 2/1 with standard 50 mg 4/2 dosing.¹¹⁷ It demonstrated that initiating treatment with 50 mg 2/1 significantly prolonged PFS compared to 50 mg 4/2 (HR: 0.75 [95%CI: 0.60-0.94]), while no difference was seen for OS. Additionally, switching from 50 mg 4/2 to 50 mg

2/1 resulted in a trend toward improved PFS (HR: 0.4 [95%CI: 0.14-1.12]). In terms of safety, the standard dose 50 mg 4/2 was associated with significantly higher odds of grade 3-4 hand-foot syndrome compared with the alternative 50 mg 2/1 (OR:0.33 [95%CI 0.12-0.79]).

Other reduced or alternative regimens have also been reported. Boegemann et al⁹⁵ conducted a retrospective analysis including 297 mRCC patients receiving sunitinib as first-line therapy, comparing those who remain on 50 mg 4/2 standard dose with those who underwent subsequent treatment modification to 37.5 mg 4/2, 25 mg 4/2, or 50 mg 2/1. Patients with treatment modifications achieved significantly better outcomes compared to the standard regimen, including median time to progression (15.1 vs 3.9 months; $P < .0001$), PFS (15.1 vs 6.0; $P < .0001$), and OS (38.1 vs 13.7; $P < .0001$). However, the modification group experiences a higher frequency of AE, including diarrhea (34%/17%), fatigue (30%/11%), hand-foot syndrome (28%/10%), and stomatitis (20%/6%).

Another study, Ohba et al,¹⁰⁷ compared a reduced regimen of 50 mg QOD dose with 50 mg 4/2. Median PFS and OS were significantly longer in the 50 mg QOD group compared with the 50 mg 4/2 group (27.6 vs 6.2 and 87.1 vs 24.6 months, respectively). The incidence of dose interruption caused by AE was significantly lower in the QOD group than in the standard group (28.1% vs 56.3%, $P = .042$).¹⁰⁷

An alternative regimen of 37.5 mg 4/2 as starting dose was also explored in two studies in Asian people.^{113, 114} These studies found no significant differences in overall survival from treatment initiation (OSinitiation), overall survival from the first documented metastasis (OStotal), or PFS between the standard and attenuated dose regimens (OSinitiation: 18.3 vs 16.5 months, respectively; $P = .54$; OStotal: 27.4 vs 21.8 months, respectively; $P = .45$; PFS: 6.7 vs 7.9 months, respectively; $P = .64$). These findings were consistent with routine clinical outcomes observed in studies involving Caucasian populations. Importantly, the attenuated regimen was associated with a significant lower incidence of severe toxicities, dose delays, and dose reductions compared to standard regimen. As depicted in Table 1, the dose reduction rate for sunitinib with the initial 50 mg QD 4/2 has been reported to range from 30% to 92.7% according to the evidence from routine clinical practice.^{20, 29-33} The mean dose intensity has been reported to be approximately 34 mg QD,²⁰ aligning with the alternative 37.5 mg QD regimen.

Model-Informed Dose Based on Published Exposure Target and PK Model

Table 2 summarized the established therapeutic target range of combined sunitinib parent drug and metabo-

lite SU12662 from $C_{min,ss}$ 50 to 100 ng/mL, based on exposure-response and exposure toxicity analysis from clinical practice patients.^{118, 119} Several PK models were identified for both sunitinib and SU12662. The Diekstra model,¹²⁰ consisting of a two-compartment model for sunitinib and a biphasic distribution for SU12662, was selected due to a rigorous prospective design and good model performance. The 50 mg QD 2/1 could result in a better target attainment than the approved 50 mg QD 4/2 regimen (Figure 5). These findings are in line with what was observed in different clinical studies reported in "Clinical Routine Practice Studies of Dose Reduction and Alternative Regimens". The therapeutic target achievement calculation results (Table S1) show that 50 mg QD 2/1 achieves a similar target attainment (74%) compared to 50 mg QD 4/2 (75%), but with a lower incidence of toxicity (2% vs 14%).

Everolimus

Approved Dose and Dose-Finding Strategy

Everolimus was approved by FDA in 2009 for patients with advanced RCC after failure of treatment with sunitinib or sorafenib. Everolimus is an oral protein kinase inhibitor of the mTOR signal transduction pathway.¹²¹ The labeled dose for advanced RCC is 10 mg QD.¹²² After oral administration, everolimus is absorbed with T_{max} of approximately 1-2 h.⁵⁰ The drug exhibits a dose-proportional AUC across the dose range of 5-70 mg. Nearly complete inhibition of S6 phosphorylation, which is the major mediator of anti-tumoral effects exerted by everolimus,¹²³ at a doses of 10 mg/day and 50 mg/week, led to the recommendation that these doses should be explored further.⁵⁰

Dose-finding studies began with a Phase I trial that evaluated both weekly regimens (5, 10, 20, 30, 50, and 70 mg) and daily regimens (5 and 10 mg). These studies identified 10 mg QD as an appropriate dose based on pharmacokinetic properties and clinical safety. In the pivotal trial,¹²⁴ all patients were treated with 10 mg QD. FDA reviewers⁵⁰ conducted an exposure-response analysis using $C_{min,ss}$ and PFS data. The analysis revealed similar median PFS across all $C_{min,ss}$ subgroups (Figure 1i), indicating no apparent exposure-response relationship for efficacy. Similarly, no trend was observed when AE were plotted against $C_{min,ss}$,¹¹⁹ as shown in Figure 1j for anemia. These findings raised concerns about the appropriateness of 10 mg QD dose as starting point for routine clinical practice, given the unclear dose-response or dose-toxicity relationship. Available everolimus tablet strengths are 2.5, 5, and 10 mg for cancer patients.




Figure 5. Model-informed sunitinib dose exploration with Diekstra model.¹²⁰ Blue dashed line indicates the efficacy target $C_{min,ss} > 50$ ng/mL. Red dashed line indicates the safety target $C_{min,ss} \leq 100$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

Clinical Routine Practice Studies of Dose Reduction and Alternative Regimens

Evidence from clinical routine practice regarding everolimus in the mRCC patients is limited (Table 1). A retrospective study³⁴ included 180 mRCC patients mostly treated with everolimus as second-line therapy.³⁴ The study found that patients who required dose reductions due to AE experienced a longer time to failure (4.2 months; 95% CI 3.4-5.0) than patients without dose reduction (1.7 months; 95% CI 1.0-2.3). These findings align with the observations made by FDA, as discussed in section “Approved Dose and Dose-Finding Strategy”. Another study reported the dose reduction rate to be 6.2%¹²⁵ but due to a very short follow-up time of 28 days, it was excluded from the final summary.

Model-Informed Dose Based on Published Exposure Target and PK Model

As shown in Table 2, everolimus has a published $C_{min,ss}$ target between 10 and 26.3 ng/mL based on a model-based analysis with pooled Phase II/III clinical trials data.¹²⁶ Only one everolimus PK model could be retrieved¹²⁷ (Tanaka model¹²⁷), based on a prospective cohort routine clinical study in mRCC patients. Another model that was based on thyroid cancer exhibited same model structure with comparable simulation results.¹²⁸ Results of simulated regimens (displayed in Table S1) are shown in Figure 6. The approved 10 mg QD starting dose exhibited higher exposure than the

desired safety target while a half dose of 5 mg QD could have better therapeutic target achievement (55% vs 42%, Table S1). Overall, the approved 10 mg QD may not be suitable in routine clinical practice from both clinical evidence and simulation study. Optimizing the starting dose to 5 mg QD could be a more suitable alternative.

Nivolumab

Approved Dose and Dose-Finding Strategy

Nivolumab, an ICI, was approved for use as monotherapy in mRCC patients who have received prior anti-angiogenic therapy.¹²⁹ Its mechanism of action involves blocking the PD-1 receptor, thereby enhancing T-cell mediated immune responses against tumors.¹³⁰ The current recommended dose is either 240 mg every 2 weeks (Q2W) or 480 mg every 4 weeks (Q4W).¹³¹ Nivolumab clearance is linear over the dose range of 0.3-10 mg/kg,¹³² and time dependent, with decreasing clearance over prolonged treatment.¹³² Evidence supporting these dosing regimens was summarized in the EMA’s Clinical Pharmacology Summary,¹³³ as no specific FDA review for this indication was available.

Dose selection was informed by early clinical studies. A large Phase Ib open-label, dose-escalation, cohort-expansion study evaluated nivolumab’s anti-tumor activity and safety across multiple tumor types including mRCC. Patients received doses of 1 or 10 mg/kg,¹³⁴




Figure 6. Model-informed everolimus dose exploration with Tanaka model.¹²⁷ Blue dashed line indicates the efficacy target $C_{min,ss} > 10$ ng/mL. Red dashed line indicates the safety target $C_{min,ss} \leq 26.3$ ng/mL. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

and no MTD was observed, even at the highest dose. The safety profile was consistent across dose levels, with similar nature, frequency, and severity of AE.¹³⁵ Exposure–response analysis¹³³ included data from a Phase II (CA209010) and a Phase III trial (CA209025) comprising 569 mRCC patients. The analysis revealed a flat relationship between $C_{avg,ss}$ and OS, indicating no significant exposure–response relationship for efficacy within the investigated dose range. Subsequent efficacy-bridging evaluations¹³⁶ were conducted to compare weight-based dosing and fixed dosing using pooled exposure–response modeling. These analyses, which included data from multiple tumor types including mRCC, support similarities in the benefit-risk profiles for 240 mg Q2W, 480 mg Q4W, and 3 mg/kg Q2W. Based on these findings, all the three dose regimens were approved as labeled dose of nivolumab.

Clinical Routine Practice Studies of Dose Reduction and Alternative Regimens

Evidence from routine clinical practice regarding nivolumab use in mRCC is relatively limited (Table 1). However, a prospective cohort study¹³⁷ involving 195 mRCC patients reported that those who completed all four cycles of nivolumab, with or without ipilimumab as first-line therapy, had significantly longer PFS and OS compared to those who received fewer than four cycles ($P < .0001$). Recently, model-informed simulations^{39, 138} have been conducted to ex-

plore the feasibility of extending the dosing intervals of nivolumab. These studies suggest that alternative regimens, such as 240 mg every 6 weeks (Q6W), could potentially reduce the financial burden while maintaining equivalent efficacy. For instance, in France, this alternative dosing schedule could potentially lower the annual treatment cost from €78,744 to €26,248.³⁹ These findings highlight the possibility of implementing extended dosing intervals as a cost-effective strategy without compromising clinical outcomes while clinical trials are warranted to confirm the non-inferiority of extended interval compared to standard regimen.

Model-Informed Dose Based on Published Exposure Target and PK Model

As shown in Table 2, a previously used³⁹ putative minimal effective plasma concentration of 2.5 mg/L based on observed $C_{min,ss}$ in patients treated with nivolumab 0.1 mg/kg Q2W in a Phase I trial¹³⁹ is utilized. This concentration is about 60-fold higher than that required to occupy in vitro more than 70% of PD-1 receptors on T cells (0.04 mg/L).³⁹ One PK model of nivolumab, Zhang model,¹⁴⁰ integrating 25 clinical trials including mRCC subpopulation was retrieved and used for simulation.¹⁴⁰ As shown in Figure 7, all approved flat dose regimens, as well as weight-based dosing, achieved targets well. An alternative regimen of 360 mg Q3W had 100% PTA, which could provide more flexibility




Figure 7. Model-informed nivolumab dose exploration with Zhang model.¹⁴⁰ Blue dashed line indicates the efficacy target $C_{min,ss} > 2.5$ mg/L. The solid lines indicate median exposure. The shaded areas indicate 90% prediction interval.

for routine clinical practice. Numerical results of the simulations can be found in Table S1.

Lessons Learned

Recently, the FDA Project OPTIMUS was initiated which is intended to assist sponsors in identifying an optimal dosage for new investigational drugs for the treatment of oncologic diseases during clinical development.¹⁰ Up to now, a well-controlled randomized registration trial was required using the MTD as selected dose for the Phase III trial which was often unnecessarily high but still could achieve a favorable benefit-risk profile. However, Project OPTIMUS further aims to increase the possibility of finding the optimal dosage beyond MTD before market approval since it is more challenging to conduct dosage optimization trials post-approval.¹⁴¹ Nevertheless, according to the landmark learn-confirm concept proposed by Lewis Sheiner in 1997, a continuous learning process remains important after drug approval.¹⁴²

In the current study, several mRCC target therapies were investigated including TKIs (pazopanib, axitinib, cabozantinib, and sunitinib), an mTOR inhibitor (everolimus), and an ICI (nivolumab). In line with Project OPTIMUS, we combined data from both approval and post-approval to (a) re-examine the approved dose and dose-finding strategy, (b) summarize routine clinical practice studies on best tolerated dose,

and (c) explore model-informed optimal doses based on established therapeutic target (if available) or published evidence. Table 2 presents a final summary of the recommended starting dose regimens based of all the information retrieved in this systematic evaluation.

Our findings highlighted the limitation of the “one size fit all” dosing strategy applied to the four TKIs currently used in mRCC, except for axitinib. The starting dose of axitinib is 5 mg BID, with the option to titrate to 7-10 mg BID based on tolerability. However, its label does not recommend dose reductions below 5 mg BID even if the patient is already experiencing intolerability. The model-informed simulations of our study (Figure 3) highlight significant inter-individual variability in axitinib exposure, suggesting that not only dose titration but also dose de-escalation could have been considered at drug approval. In the case of pazopanib and cabozantinib, the approved doses appear higher than what many patients can tolerate in routine clinical practice. As shown in the simulations in Figures 2 (pazopanib) and 4 (cabozantinib), the exposure of approved dosages is higher than the toxicity threshold. Consequently, after the comprehensive evaluation presented here, the recommendation would be to reduce the starting dose to 600 mg QD for pazopanib and to 40 mg QD (or 60 mg 2 days on, 1 day off regimen) for cabozantinib (Table 2). By considering these dose reductions, a better balance between therapeutic exposure and safety could be achieved. For sunitinib,

the approved 50 mg 4/2 regimen could potentially be replaced by a 50 mg 2/1 regimen, maintaining the same dose intensity but with lower toxicity and improved PFS in routine clinical practice. Overall, a common characteristic of TKIs is their complex oral absorption process¹⁴³ and huge inter-individual variability of exposure,¹⁴⁴ which means that different doses may highly lead to considerably overlapping proportions of the 95% percentiles of the model-informed simulations from a population perspective. Therefore, starting at a lower dose with model-informed individualization to ensure that the patient stays within the therapeutic window could improve the treatment tolerability, lead to less drug discontinuation, and potentially decrease the risk of disease recurrence and treatment failure.

For the mTOR inhibitor everolimus, the dose-finding process was similar to that of TKIs, with a flat dose-response relationship and clear exposure-toxicity relationship. However, everolimus was registered at a high dose of 10 mg QD, which could be an unnecessarily higher dose based on both exposure-response analysis from clinical trials data and routine clinical practice studies. A pre-published TDM target for everolimus (C_{min} range of 10–26.3 ng/mL) generated from a model-based analysis of pooled clinical trials data,¹²⁶ and our simulation results depicted in Figure 6, indicated that 7.5 or 5 mg QD could result in a higher target attainment rate and therefore be more suitable starting regimens, rather than 10 mg QD.

When it comes to ICIs, nivolumab is currently used as monotherapy or in combination with ipilimumab or cabozantinib as one of the standard treatments in previously untreated mRCC patients. Although nivolumab has demonstrated significantly improved survival, due to its high cost, accessibility remains a challenge worldwide.¹⁴⁵ Despite the fact that limited routine clinical practice evidence was retrieved for mRCC patients, our simulations suggested that approved flat dose regimens could achieve sufficient drug exposure. Nevertheless, there are currently other dose optimization strategies being explored including reduced unit dose, less frequent schedule, and/or shorter duration of treatment.¹⁴⁶ For example, a Phase III randomized controlled trial (RCT) is enrolling mRCC patients who have responded to nivolumab for 1 year, to either discontinue or continue treatment (jRCT1031200071). For other tumor types, there are also many attempts to decrease the treatment intervals and treatment dose. One retrospective, non-randomized, study compared the efficacy of nivolumab 20 and 100 mg Q2W among patients with hepatocellular carcinoma.¹⁴⁷ The study indicated that 20 mg Q2W had a longer PFS than those who received 100 mg Q2W (4.5 months vs 2.3 months, $P = .007$).¹⁴⁷

To sum up, based on the results of all investigated targeted therapies and ICIs, except for axitinib, the approved fixed-dose regimens are either higher than the doses actually tolerated in routine clinical practice for small molecules^{46, 48–50} or are unnecessarily high due to the flat exposure-response/exposure–toxicity relationships, as in the case of nivolumab.¹³³ Therefore, it is crucial that the focus should not only be identifying the optimal dose for the patient population as a whole, since considerable inter-patient variability in exposure will remain present with fixed dosing. Ideally, the optimal exposure range should also be reported which can subsequently be used for pharmacokinetically guided dose individualization in the clinic.

Therapeutic alternatives for treating mRCC are increasing, with combination therapies including anti-angiogenic agents and tyrosine kinase/mTOR/ICIs now considered as the gold standard, as supported by recent clinical studies.¹⁴⁸ These combination therapies have been evaluated using various trial designs, including sequential escalation, parallel escalation, monotherapy lead-in (intra-patient crossover), and combination escalation.¹⁴⁹ However, despite these advancements, the dose-finding strategies and exposure-response relations for approved combination regimens in mRCC patients remain poorly defined. Recent recommendations advocate for the integration of a quantitative clinical pharmacology framework in dose-finding studies for combination therapy. This approach combines data from in vitro, preclinical in vivo, and clinical trials, along with insight from competitive therapeutic landscape.¹⁵⁰ While promising, evidence from routine clinical practice for these combination therapies in mRCC remains scarce and was therefore not discussed in this study. Given the increasing reliance on combination therapies for mRCC treatment, it is critical to prioritize efforts in optimizing dose regimens. Such optimization will ensure that these therapies deliver their full potential in terms of efficacy and safety within routine clinical practice.¹⁴⁸

It is emphasized that the Phase III RCTs are the most rigorous way of determining whether a favorable benefit-risk relation exists between treatment regimen and outcome.¹⁵¹ In the current study, we leveraged and interpolated the dose regimens that had been investigated in early phase dose-finding trials with exposure simulations and included efficacy and toxicity data from routine clinical practice. This approach could be useful for future study designs or even serve as pivotal evidence to support the approval of untested doses which is as often applied in the pediatric population.¹⁵² In addition, FDA recently published a guideline to support the development of alternative dosing regimens for anti-PD-1/PD-L1 antibodies that are derived from a PK-based model-informed approach.¹⁵³ This shows

that modeling and simulation is an important tool to develop alternative dose regimens suitable for application in clinical practice. This approach has, thus far, been employed to develop fixed dosing regimens and prolonged dosing intervals for the purposes of patient and prescriber convenience.¹⁵⁴ To sum up, the final recommendations of the present study, which are based on interpolation of regulatory registration data, routine clinical evidence, and PK simulations, should be further evaluated in clinical practice and/or clinical trials.

Lastly, while our study provides valuable insights into dosing strategies for targeted therapies in mRCC, it also has certain limitations. Our analysis was limited to therapies with available data on three key points: (1) the approved dose and dose-finding strategy, (2) drug tolerance and alternative regimens in clinical practice, and (3) well-defined exposure targets for model-informed simulations. Consequently, combination therapies and newer treatments such as tivozanib were not included. In the present study, evidence from routine clinical practice observational studies were summarized and most of these observational studies had a non-randomized, retrospective design which may be susceptible to confounding and selection bias.¹⁵⁵ Furthermore, although we selected a representative pharmacokinetic model for each drug based on a predefined approach, alternative models might yield different outcomes. Future research could expand on comparing different published models to refine our understanding. Despite these limitations, our study offers valuable guidance on optimizing dosing strategies to improve the efficacy and tolerability of targeted therapies and check point inhibitors in clinical practice.

Conclusion

This study comprehensively evaluates the opportunities of dose optimization of approved mRCC target therapies and ICIs in the context of Project OPTIMUS. Through a combination of literature review, real world evidence on toxicity and efficacy, and model-informed simulations, we identified optimized dosing regimens that could improve drug tolerability while maintaining efficacy. We recommend that these optimized dosing regimens should be considered for further evaluation and that the optimal exposure range should be included in drug labels to support pharmacokinetically guided dose individualization in clinical practice.

Acknowledgments

Not Applicable.

Conflicts of Interest

The authors declare no conflicts of interest.

Funding

The work of Zhiyuan Tan was supported by the China Scholarship Council (202108310028).

Data Availability Statement

Not Applicable.

References

1. Pontes O, Oliveira-Pinto S, Baltazar F, Costa M. Renal cell carcinoma therapy: current and new drug candidates. *Drug Discov Today*. 2022;27(1):304-314. doi:10.1016/j.drudis.2021.07.009
2. Medina López RA, Rivero Belenchon I, Mazuecos-Quirós J, Congregado-Ruiz CB, Couñago F. Update on the treatment of metastatic renal cell carcinoma. *World J Clin Oncol*. 2022;13(1):1-8. doi:10.5306/wjco.v13.i1.1
3. Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. *Nat Rev Nephrol*. 2017;13(8):496-511. doi:10.1038/nrneph.2017.82
4. Ravaud A, Gross-Goupil M. Overcoming resistance to tyrosine kinase inhibitors in renal cell carcinoma. *Cancer Treat Rev*. 2012;38(8):996-1003. doi:10.1016/j.ctrv.2012.01.003
5. Liu Y-F, Zhang Z-C, Wang S-Y, et al. Immune checkpoint inhibitor-based therapy for advanced clear cell renal cell carcinoma: A narrative review. *Int Immunopharmacol*. 2022;110:108900. doi:10.1016/j.intimp.2022.108900
6. Gurram S, Al Harthy M, Ball MW. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update. *Discov Med*. 2020;29(158):191-199.
7. Hizal M, Sendur MAN, Bilgin B, Akinci MB, Sener Dede D, Yalcin B. A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. *Curr Med Res Opin*. 2020;36(4):625-635. doi:10.1080/03007995.2020.1716705
8. Ajithkumar TV, Hatcher HM. 25 - Clinical trials in cancer. In: Ajithkumar TV, Hatcher HM, eds. *Specialist Training in Oncology*. Mosby; 2011:355-359.
9. Le Tourneau C, Gan HK, Razak AR, Paoletti X. Efficiency of new dose escalation designs in dose-finding phase I trials of molecularly targeted agents. *PLoS One*. 2012;7(12):e51039. doi:10.1371/journal.pone.0051039
10. FDA. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases, Guidance for Industry (2024). Docket Number: FDA-2022-D-2827
11. Jänne PA, Kim G, Shaw AT, Sridhara R, Pazdur R, McKee AE. Dose finding of small-molecule oncology drugs: optimization throughout the development life cycle. *Clin Cancer Res*. 2016;22(11):2613-2617. doi:10.1158/1078-0432.Ccr-15-2643
12. Verheijen RB, Atrafi F, Schellens JHM, et al. Pharmacokinetic optimization of everolimus dosing in oncology: a randomized crossover trial. *Clin Pharmacokinet*. 2018;57(5):637-644. doi:10.1007/s40262-017-0582-9
13. Shah M, Rahman A, Theoret MR, Pazdur R. The drug-dosing conundrum in oncology - when less is more. *N Engl J Med*. 2021;385(16):1445-1447. doi:10.1056/NEJMp2109826
14. Bei D, Osawa M, Uemura S, et al. Benefit-risk assessment of nivolumab 240 mg flat dose relative to 3 mg/kg Q2W regimen in Japanese patients with advanced cancers. *Cancer Sci*. 2020;111(2):528-535. doi:10.1111/cas.14252
15. Patil VM, Noronha V, Menon N, et al. Low-dose immunotherapy in head and neck cancer: a randomized study. *J Oncol Pract*. 2023;41(2):222-232. doi:10.1200/jco.22.01015

16. Gendy JM, Nomura N, Stuart JN, Blumenthal G. US FDA's dose optimization postmarketing requirements and commitments of oncology approvals and the impact on product labels from 2010 to 2022: an emerging landscape from traditional to novel therapies. *Ther Innov Regul Sci*. 2024;58(2):380-386. doi:10.1007/s43441-023-00606-1
17. Moon H. FDA initiatives to support dose optimization in oncology drug development: the less may be the better. *Transl Clin Pharmacol*. 2022;30(2):71-74. doi:10.12793/tcp.2022.30.e9
18. Shah AY, Kotecha RR, Lemke EA, et al. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors. *Eur J Cancer*. 2019;114:67-75. doi:10.1016/j.ejca.2019.04.003
19. Johnston H, Deal AM, Morgan KP, Patel B, Milowsky MI, Rose TL. Dose intensity in real-world patients with metastatic renal cell carcinoma taking vascular endothelial growth factor receptor tyrosine kinase inhibitors. *Clin Genitourinary Cancer*. 2023;21(3):357-365. doi:10.1016/j.clgc.2023.02.007
20. Gaillard V, Lhuillier A, Bigot C, et al. Impact of the app-based and nurse-led supportive care program AKO@dom on dose intensity of oral-targeted therapies in patients with metastatic renal cell cancer: a multicentric observational retrospective study. *Support Care Cancer*. 2022;30(8):6583-6591. doi:10.1007/s00520-022-07088-1
21. Masini C, Vitale MG, Maruzzo M, et al. Safety and efficacy of pazopanib in first-line metastatic renal-cell carcinoma with or without renal failure: CORE-URO-01 study. *Clin Genitourin Cancer*. 2019;17(1):e150-e155. doi:10.1016/j.clgc.2018.10.001
22. Albiges L, Fléchon A, Chevreau C, et al. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: results from the CABOREAL early access program. *Eur J Cancer*. 2021;142:102-111. doi:10.1016/j.ejca.2020.09.030
23. Krens SD, van Erp NP, Groenland SL, et al. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer. *BMC Cancer*. 2022;22(1):228. doi:10.1186/s12885-022-09338-1
24. Campbell MT, Bilen MA, Shah AY, et al. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: a retrospective analysis. *Eur J Cancer*. 2018;104:188-194. doi:10.1016/j.ejca.2018.08.014
25. Gan CL, Dudani S, Wells JC, et al. Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. *Cancer Med*. 2021;10(4):1212-1221. doi:10.1002/cam4.3717
26. Martini DJ, Evans ST, Liu Y, et al. Analysis of toxicity and clinical outcomes in full versus reduced starting dose cabozantinib in metastatic renal cell carcinoma patients. *Clin Genitourin Cancer*. 2022;20(1):53-59. doi:10.1016/j.clgc.2021.11.004
27. Prisciandaro M, Ratta R, Massari F, et al. Safety and efficacy of cabozantinib for metastatic nonclear renal cell carcinoma: real-world data from an Italian managed access program. *Am J Clin Oncol*. 2019;42(1):42-45. doi:10.1097/coc.0000000000000478
28. McElwee JH, Gourdin TS, Mikoll J, Weeda E, Sion AM. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials. *J Oncol Pharm*. 2020;26(4):861-865. doi:10.1177/1078155219875509
29. Porta C, Paglino C, Imarisio I, et al. Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy. *BMC Cancer*. 2011;11:105. doi:10.1186/1471-2407-11-105
30. Park SJ, Lee JL, Park I, et al. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma. *Chemotherapy*. 2012;58(6):468-474. doi:10.1159/000346484
31. Miyake H, Miyazaki A, Harada K, Fujisawa M. Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan. *Med Oncol*. 2014;31(6):978. doi:10.1007/s12032-014-0978-4
32. Abd Ghafar NK, Alip A, Ong TA, Yap NY, Saad M. Efficacy, safety, and prognostic indicators of first-line sunitinib in patients with metastatic renal cell carcinoma: a single center experience. *J Cancer Res Ther*. 2018;14(6):1303-1311. doi:10.4103/0973-1482.189247
33. Noize P, Grelaud A, Bay JO, et al. Real-life patterns of use, safety and effectiveness of sunitinib in first-line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study. *Pharmacoevidenciol Drug Saf*. 2017;26(12):1561-1569. doi:10.1002/pds.4228
34. Nozawa M, Nonomura N, Ueda T, et al. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice. *Jpn J Clin Oncol*. 2013;43(11):1132-1138. doi:10.1093/jco/hyt121
35. Puisset F, Mseddi M, Mourey L, et al. Therapeutic drug monitoring of tyrosine kinase inhibitors in the treatment of advanced renal cancer. *Cancers*. 2023;15(1):313.
36. Mueller-Schoell A, Groenland SL, Scherf-Clavel O, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. *Eur J Clin Pharmacol*. 2021;77(4):441-464. doi:10.1007/s00228-020-03014-8
37. Henriksen JN, Andersen CU, Frstrup N. Therapeutic drug monitoring for tyrosine kinase inhibitors in metastatic renal cell carcinoma. *Clin Genitourin Cancer*. 2024;22(3):102064. doi:10.1016/j.clgc.2024.102064
38. Blanchet B, Xu-Vuillard A, Jouinot A, et al. Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care. *Br J Cancer*. 2024;130(6):961-969. doi:10.1038/s41416-024-02585-y
39. Puskiel A, Bianconi G, Pasquiers B, et al. Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients. *Br J Cancer*. 2024;130(11):1866-1874. doi:10.1038/s41416-024-02659-x
40. Guo Y, Guo T, Knibbe CAJ, Zwep LB, van Hasselt JGC. Generation of realistic virtual adult populations using a model-based copula approach. *J Pharmacokinet Pharmacodyn*. 2024;51:735-746. doi:10.1007/s10928-024-09929-4
41. FDA. Label of VOTRIENT (pazopanib) tablets (Revised on 1/2024). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022465s0361bl.pdf
42. Kasper B, Hohenberger P. Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. *Future Oncol*. 2011;7(12):1373-1383. doi:10.2217/fon.11.116
43. Pick AM, Nystrom KK. Pazopanib for the treatment of metastatic renal cell carcinoma. *Clin Ther*. 2012;34(3):511-520. doi:10.1016/j.clinthera.2012.01.014
44. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. *Clin Cancer Res*. 2009;15(12):4220-4227. doi:10.1158/1078-0432.Ccr-08-2740
45. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. *N Engl J Med*. 2013;369(8):722-731. doi:10.1056/NEJMoa1303989
46. CENTER FOR DRUG EVALUATION AND RESEARCH, FDA. VOTRIENT (pazopanib) tablets CLINICAL

- PHARMACOLOGY AND BIPHARMACEUTICS REVIEW. 2008. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022465s000_ClinPharmR.pdf
47. CENTER FOR DRUG EVALUATION AND RESEARCH, FDA. INLYTA® (axitinib) tablets CLINICAL PHARMACOLOGY AND BIPHARMACEUTICS REVIEW. 2012. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/20324Orig1s000ClinPharmR.pdf
 48. CENTER FOR DRUG EVALUATION AND RESEARCH, FDA. CABOMETYX™ (cabozantinib) tablets CLINICAL PHARMACOLOGY AND BIPHARMACEUTICS REVIEW. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000ClinPharmR.pdf
 49. CENTER FOR DRUG EVALUATION AND RESEARCH, FDA. SUTENT® (sunitinib malate) capsules CLINICAL PHARMACOLOGY AND BIPHARMACEUTICS REVIEW. 2005. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/021938_S000_Sutent_BioPharmR.pdf
 50. CENTER FOR DRUG EVALUATION AND RESEARCH, FDA. AFINITOR (everolimus) tablets CLINICAL PHARMACOLOGY AND BIPHARMACEUTICS REVIEW. 2008. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022334s000_ClinPharmR.pdf
 51. Corianò M, Giannarelli D, Scartabellati G, et al. Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome? *Expert Rev Anticancer Ther*. 2023;23(5):545-554. doi:10.1080/14737140.2023.2200168
 52. Iacovelli R, Cossu Rocca M, Galli L, et al. Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer. *Urol Oncol*. 2017;35(9):541.e7-541.e13. doi:10.1016/j.urolonc.2017.05.007
 53. Grassi P, Verzoni E, Ratta R, et al. Does dose modification affect efficacy of first-line pazopanib in metastatic renal cell carcinoma? *Drugs R D*. 2017;17(3):461-467. doi:10.1007/s40268-017-0203-y
 54. Bins S, Huitema ADR, Laven P, et al. Impact of CYP3A4*22 on pazopanib pharmacokinetics in cancer patients. *Clin Pharmacokinet*. 2019;58(5):651-658. doi:10.1007/s40262-018-0719-5
 55. Ozbey AC, Combarel D, Poinsignon V, et al. Population pharmacokinetic analysis of pazopanib in patients and determination of target AUC. *Pharmaceuticals*. 2021;14(9):927. doi:10.3390/ph14090927
 56. Yu H, van Erp N, Bins S, et al. Development of a pharmacokinetic model to describe the complex pharmacokinetics of pazopanib in cancer patients. *Clin Pharmacokinet*. 2017;56(3):293-303. doi:10.1007/s40262-016-0443-y
 57. Tan Z, Völler S, Yin A, et al. Model-Informed Dose Optimization of Pazopanib in Real-World Patients with Cancer. *Clin Pharmacokinet*. 2025. doi:10.1007/s40262-025-01504-5
 58. FDA. Label of INLYTA® (axitinib) tablets (Revised on 7/2024). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/20324s016lbl.pdf
 59. Chen Y, Suzuki A, Tortorici MA, et al. Axitinib plasma pharmacokinetics and ethnic differences. *Invest New Drugs*. 2015;33(2):521-532. doi:10.1007/s10637-015-0214-x
 60. Chen Y, Tortorici MA, Garrett M, Hee B, Klamers KJ, Pithavala YK. Clinical pharmacology of axitinib. *Clin Pharmacokinet*. 2013;52(9):713-725. doi:10.1007/s40262-013-0068-3
 61. Yasuoka S, Yuasa T, Fujiwara R, et al. Efficacy and safety of axitinib therapy after nivolumab for patients with metastatic renal cell cancer. *Anticancer Res*. 2020;40(11):6493-6497. doi:10.21873/anticancer.14671
 62. Synowiec Z, Sobańska K, Synowiec T, Teżyk A, Tomczak P, Jabłeczka A. Axitinib trough concentration and its influence on the efficacy and toxicity of second-line renal cell carcinoma treatment. *Clin Genitourin Cancer*. 2022;20(4):390.e1-390.e8. doi:10.1016/j.clgc.2022.03.006
 63. Fukudo M, Tamaki G, Azumi M, Kakizaki H, Matsumoto S, Tasaki Y. Absorption of the orally active multikinase inhibitor axitinib as a therapeutic index to guide dose titration in metastatic renal cell carcinoma. *Invest New Drugs*. 2021;39(2):595-604. doi:10.1007/s10637-020-01023-z
 64. Chen Y, Rini BI, Bair AH, Mugundu GM, Pithavala YK. Population pharmacokinetic-pharmacodynamic modelling of 24-h diastolic ambulatory blood pressure changes mediated by axitinib in patients with metastatic renal cell carcinoma. *Clin Pharmacokinet*. 2015;54(4):397-407. doi:10.1007/s40262-014-0207-5
 65. Garrett M, Poland B, Brennan M, Hee B, Pithavala YK, Amantea MA. Population pharmacokinetic analysis of axitinib in healthy volunteers. *Br J Clin Pharmacol*. 2014;77(3):480-492. doi:10.1111/bcp.12206
 66. Rini BI, Garrett M, Poland B, et al. Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis. *J Clin Pharmacol*. 2013;53(5):491-504. doi:10.1002/jcph.73
 67. Srigadha VK, Prabhash K, Noronha V, et al. Cabozantinib: a narrative drug review. *Cancer Research, Statistics, and Treatment*. 2023;6(1):74-87. doi:10.4103/crst.crst_9_23
 68. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. *Mol Cancer Ther*. 2011;10(12):2298-2308.
 69. FDA. Label of CABOMETYX™ (cabozantinib) tablets (Revised on 3/2025). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208692s017lbl.pdf
 70. Tan Z, Völler S, Yin A, et al. Population pharmacokinetics of cabozantinib in metastatic renal cell carcinoma patients: towards drug expenses saving regimens. *Clin Pharmacokinet*. 2024;63(6):857-869. doi:10.1007/s40262-024-01379-y
 71. Lacy S, Nielsen J, Yang B, Miles D, Nguyen L, Huttmacher M. Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma. *Cancer Chemother Pharmacol*. 2018;81(6):1061-1070. doi:10.1007/s00280-018-3579-7
 72. Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2016;17(7):917-927. doi:10.1016/s1470-2045(16)30107-3
 73. Lacy S, Yang B, Nielsen J, Miles D, Nguyen L, Huttmacher M. A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types. *Cancer Chemother Pharmacol*. 2018;81(6):1071-1082. doi:10.1007/s00280-018-3581-0
 74. Bruchbacher A, Franke J, Alimohammadi A, Laukhtina E, Fajkovic H, Schmidinger M. Real-world results of cabozantinib given as alternative schedule in metastatic renal cell carcinoma. *Clin Genitourin Cancer*. 2023;22:98-108. doi:10.1016/j.clgc.2023.09.006
 75. McGregor BA, Lalani AA, Xie W, et al. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma. *Eur J Cancer*. 2020;135:203-210. doi:10.1016/j.ejca.2020.05.009
 76. Procopio G, Prisciandaro M, Iacovelli R, et al. Safety and efficacy of cabozantinib in metastatic renal-cell carcinoma:

- real-world data from an Italian managed access program. *Clinical genitourinary cancer*. 2018;16(4):e945-e951. doi:10.1016/j.clgc.2018.03.014
77. Procopio G, Sepe P, Claps M, et al. Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI trial for the Italian network for research in urologic-oncology (Meet-URO 2 study). *JAMA Oncol*. 2022;8(6):910-913. doi:10.1001/jamaoncol.2022.0238
 78. CDER. Clinical pharmacology and biopharmaceutics review(s) of cabometyx. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208692Orig1s000TOC.cfm
 79. Nguyen L, Chapel S, Tran BD, Lacy S. Updated population pharmacokinetic model of cabozantinib integrating various cancer types including hepatocellular carcinoma. *J Clin Pharmacol*. 2019;59(11):1551-1561. doi:10.1002/jcph.1467
 80. Le Tourneau C, Raymond E, Faivre S. Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST). *Ther Clin Risk Manage*. 2007;3(2):341-348. doi:10.2147/tcrm.2007.3.2.341
 81. FDA. Label of SUTENT® (sunitinib malate) capsules (Revised on 2/2007). https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021968s002s003s004s005s0061bl.pdf
 82. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *J Oncol Pract*. 2006;24(1):25-35. doi:10.1200/jco.2005.02.2194
 83. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. *N Engl J Med*. 2007;356(2):115-124. doi:10.1056/NEJMoa065044
 84. Ansari J, Fatima A, Fernando K, Collins S, James ND, Porfiri E. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience. *Oncol Rep*. 2010;24(2):507-510. doi:10.3892/or_00000886
 85. Brunello A, Basso U, Sacco C, et al. Safety and activity of sunitinib in elderly patients (≥ 70 years) with metastatic renal cell carcinoma: a multicenter study. *Ann Oncol*. 2013;24(2):336-342. doi:10.1093/annonc/mds431
 86. Fujita T, Hirayama T, Nishi M, Matsumoto K, Yoshida K, Iwamura M. Outcome of third-line sunitinib after sequential therapy with cytokines and sorafenib in metastatic renal cell carcinoma. *Mol Clin Oncol*. 2019;11(5):505-510. doi:10.3892/mco.2019.1924
 87. Ishihara H, Takagi T, Kondo T, et al. Decreased relative dose intensity during the early phase of treatment impacts the therapeutic efficacy of sunitinib in metastatic renal cell carcinoma. *Jpn J Clin Oncol*. 2018;48(7):667-672. doi:10.1093/jjco/hyy078
 88. Iwamoto K, Ishihara H, Takagi T, et al. Evaluation of relative dose intensity during the early phase of first-line sunitinib treatment using a 2-week-on/1-week-off regimen for metastatic renal cell carcinoma. *Med Oncol*. 2018;35(6):78. doi:10.1007/s12032-018-1139-y
 89. Josephs D, Hutson TE, Cowey CL, et al. Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis. *BJU Int*. 2011;108(8):1279-1283. doi:10.1111/j.1464-410X.2010.09990.x
 90. Kawashima A, Tsujimura A, Takayama H, et al. Importance of continuing therapy and maintaining one-month relative dose intensity in sunitinib therapy for metastatic renal cell carcinoma. *Med Oncol*. 2012;29(5):3298-3305. doi:10.1007/s12032-012-0236-6
 91. Livne-Segev D, Gottfried M, Maimon N, et al. Experience with sunitinib treatment for metastatic renal cell carcinoma in a large cohort of Israeli patients: outcome and associated factors. *IMAJ*. 2014;16(6):347-351.
 92. Poprach A, Lakomy R, Bortliczek Z, et al. Efficacy of sunitinib in elderly patients with metastatic renal cell carcinoma: data from real-world clinical practice. *Drugs Aging*. 2016;33(9):655-663. doi:10.1007/s40266-016-0390-1
 93. Yildiz I, Ekenel M, Akman T, et al. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a multicenter retrospective Turkish oncology group trial. *Anticancer Res*. 2014;34(8):4329-4334.
 94. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. *J Urol*. 2014;191(3):611-618. doi:10.1016/j.juro.2013.08.090
 95. Boegemann M, Hubbe M, Thomaidou D, et al. Sunitinib treatment modification in first-line metastatic renal cell carcinoma: analysis of the STAR-TOR registry. *Anticancer Res*. 2018;38(11):6413-6422. doi:10.21873/anticancer.13002
 96. Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. *Ann Oncol*. 2015;26(10):2107-2113. doi:10.1093/annonc/mdv315
 97. Buti S, Donini M, Bersanelli M, Gattara A, Leonardi F, Passalacqua R. Feasibility, safety, and efficacy of an alternative schedule of sunitinib for the treatment of patients with metastatic renal cell carcinoma: a retrospective study. *Drugs R D*. 2017;17(4):585-596. doi:10.1007/s40268-017-0209-5
 98. Buti S, Donini M, Lazzarelli S, Passalacqua R. A new modified schedule of sunitinib for metastatic renal cell carcinoma: a retrospective analysis. *Acta Bio-Medica : Atenei Parmensis*. 2012;83(2):88-94.
 99. Cheng W, Kletas V, Kollmannsberger C, de Lemos M. Survival outcomes associated with different sunitinib dosing regimens in metastatic renal cell carcinoma. *J Oncol Pharm*. 2020;26(1):67-73. doi:10.1177/1078155219837333
 100. Crumbaker M, Guminski A, Gurney H, Sabanathan D, Wong S, Pavlakis N. Real-world experience of the feasibility and tolerability of the 2/1 dosing schedule with sunitinib in the treatment of patients with advanced renal cell carcinoma in Australia. *Asia Pac J Clin Oncol*. 2018;14(2):e45-e49. doi:10.1111/ajco.12686
 101. De Giorgi U, Scarpi E, Sacco C, et al. Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. *Clin Genitourin Cancer*. 2014;12(3):182-189. doi:10.1016/j.clgc.2013.11.005
 102. Ezz El Din M. Sunitinib 4/2 versus 2/1 schedule for patients with metastatic renal cell carcinoma: tertiary care hospital experience. *Clin Genitourin Cancer*. 2017;15(3):e455-e462. doi:10.1016/j.clgc.2016.10.010
 103. Makino K, Yoda K, Tomoishi J, Kume H. Efficacy and tolerability of a low-dose, 2-week administration of sunitinib followed by a week rest (2/1 schedule) for metastatic renal cell carcinoma: a single center experience of six cases. *BMC Res Notes*. 2014;7:872. doi:10.1186/1756-0500-7-872
 104. Miyake H, Harada K, Miyazaki A, Fujisawa M. Improved health-related quality of life of patients with metastatic renal cell carcinoma treated with a 2 weeks on and 1 week off schedule of sunitinib. *Med Oncol*. 2015;32(3):78. doi:10.1007/s12032-015-0528-8
 105. Miyake H, Matsushita Y, Watanabe H, et al. Significance of introduction of alternative dosing schedule for sunitinib during first-line treatment of patients with metastatic renal cell

- carcinoma. *Med Oncol*. 2018;35(10):133. doi:10.1007/s12032-018-1195-3
106. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. *Eur J Cancer*. 2014;50(6):1084-1089. doi:10.1016/j.ejca.2014.01.025
 107. Ohba K, Miyata Y, Mitsunari K, et al. Alternative treatment with every-other-day dosing of sunitinib for metastatic renal cell carcinoma: extended follow-up. *Urol Int*. 2022;106(6):623-629. doi:10.1159/000520652
 108. Ohba K, Miyata Y, Yasuda T, et al. Efficacy and safety of sunitinib alternate day regimen in patients with metastatic renal cell carcinoma in Japan: comparison with standard 4/2 schedule. *Asia Pac J Clin Oncol*. 2018;14(3):153-158. doi:10.1111/ajco.12849
 109. Ohzeki T, Fukasawa S, Komaru A, et al. Efficacy of traditional and alternative sunitinib treatment schedules in Japanese patients with metastatic renal cell carcinoma. *Int J Urol*. 2014;21(10):1065-1068. doi:10.1111/iju.12504
 110. Rizza L, Sbardella E, Gianfrilli D, et al. Thyroid profile during the alternative sunitinib dosing 2/1 schedule in metastatic renal cell carcinoma. *Endocrine*. 2020;67(3):597-604. doi:10.1007/s12020-019-02088-4
 111. Smaletz O, Chacón M, de Oliveira Koch L, de Carvalho Rocha DR, Cardoso FC. Long-term benefit of sunitinib in patients with metastatic renal cell carcinoma in Latin America: retrospective analysis of patient clinical characteristics. *OncoTargets Ther*. 2016;9:7309-7314. doi:10.2147/ott.S111137
 112. Suo A, Iqbal U, Lim J, et al. Outcomes and drug costs of sunitinib regimens for metastatic renal cell carcinoma: a provincial population-based study. *Clin Genitourin Cancer*. 2017;15(3):e397-e404. doi:10.1016/j.clgc.2017.01.016
 113. Tan HS, Li H, Hong YW, et al. Efficacy and safety of an attenuated-dose sunitinib regimen in metastatic renal cell carcinoma: results from a prospective eegistry in Singapore. *Clin Genitourin Cancer*. 2015;13(4):e285-e295. doi:10.1016/j.clgc.2014.11.004
 114. Teo YL, Chue XP, Chau NM, et al. Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. *Targeted Oncol*. 2015;10(3):429-437. doi:10.1007/s11523-014-0349-2
 115. Yamada Y, Ohno Y, Kato Y, et al. Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma. *Cancer Chemother Pharmacol*. 2019;84(5):987-992. doi:10.1007/s00280-019-03935-x
 116. Yildiz I, Sen F, Basaran M, et al. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey. *Jpn J Clin Oncol*. 2011;41(12):1380-1387. doi:10.1093/jjco/hyr151
 117. Abogunrin S, Ashaye AO, Cappelleri JC, et al. Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis. *Future Oncol*. 2019;15(18):2175-2190. doi:10.2217/fon-2018-0858
 118. Noda S, Otsuji T, Baba M, et al. Assessment of sunitinib-induced toxicities and clinical outcomes based on therapeutic drug monitoring of sunitinib for patients with renal cell carcinoma. *Clin Genitourin Cancer*. 2015;13(4):350-358. doi:10.1016/j.clgc.2015.01.007
 119. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *J Clin Oncol*. 2006;24(1):25-35. doi:10.1200/JCO.2005.02.2194
 120. Diekstra MH, Fritsch A, Kanefendt F, et al. Population modeling integrating pharmacokinetics, pharmacodynamics, pharmacogenetics, and clinical outcome in patients with sunitinib-treated cancer. *CPT: Pharmacomet Syst Pharmacol*. 2017;6(9):604-613. doi:10.1002/psp4.12210
 121. Hasskarl J. Everolimus. *Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer*. 2018;211:101-123. doi:10.1007/978-3-319-91442-8_8
 122. FDA. Label of AFINITOR (everolimus) tablets for oral administration (Revised on 2/2022). https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/203985s023_022334s0511bl.pdf
 123. Knoll M, Macher-Goeppinger S, Kopitz J, et al. The ribosomal protein S6 in renal cell carcinoma: functional relevance and potential as biomarker. *Oncotarget*. 2016;7(1):418-432. doi:10.18632/oncotarget.6225
 124. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. *Lancet*. 2008;372(9637):449-456. doi:10.1016/s0140-6736(08)61039-9
 125. Maráz A, Csejtei A, Kocsis J, et al. Assessment of the role of everolimus therapy in patients with renal cell carcinoma based on daily routine and recent research results. *Pathol Oncol Res: POR*. 2019;25(1):149-156. doi:10.1007/s12253-017-0317-0
 126. Ravaud A, Urva SR, Grosch K, Cheung WK, Anak O, Sellami DB. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. *Eur J Cancer*. 2014;50(3):486-495. doi:10.1016/j.ejca.2013.11.022
 127. Tanaka A, Yano I, Shinsako K, et al. Population pharmacokinetics of everolimus in relation to clinical outcomes in patients with advanced renal cell carcinoma. *Ther Drug Monit*. 2016;38(6):663-669. doi:10.1097/ftd.0000000000000344
 128. de Wit D, Schneider TC, Moes DJAR, et al. Everolimus pharmacokinetics and its exposure-toxicity relationship in patients with thyroid cancer. *Cancer Chemother Pharmacol*. 2016;78(1):63-71. doi:10.1007/s00280-016-3050-6
 129. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. *N Engl J Med*. 2015;373(19):1803-1813. doi:10.1056/NEJMoa1510665
 130. Meybodi SM, Farasati Far B, Pourmolaei A, et al. Immune checkpoint inhibitors promising role in cancer therapy: clinical evidence and immune-related adverse events. *Med Oncol*. 2023;40(8):243. doi:10.1007/s12032-023-02114-6
 131. FDA. Label of OPDIVO (nivolumab) injection (Revised on 2/2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125554s1321bl.pdf
 132. Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. *CPT: Pharmacomet Syst Pharmacol*. 2017;6(1):58-66. doi:10.1002/psp4.12143
 133. EMA. Clinical reports for OPDIVO - Extension of Indication Advanced Metastatic Renal Cell Carcinoma. Module 2.7.2 Summary of Clinical Pharmacology. (2015). <https://www.ema.europa.eu>
 134. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med*. 2012;366(26):2443-2454. doi:10.1056/NEJMoa1200690
 135. Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. *J Immunother Cancer*. 2016;4:72. doi:10.1186/s40425-016-0177-2
 136. Zhao X, Shen J, Ivaturi V, et al. Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across

- multiple tumor types. *Ann Oncol*. 2020;31(2):302-309. doi:10.1016/j.annonc.2019.10.015
137. Thana M, Basappa NS, Ghosh S, et al. Utilization and safety of ipilimumab plus nivolumab in a real-world cohort of metastatic renal cell carcinoma patients. *Clin Genitourin Cancer*. 2022;20(3):210-218. doi:10.1016/j.clgc.2021.12.003
 138. Peer CJ, Heiss BL, Goldstein DA, Goodell JC, Figg WD, Ratain MJ. Pharmacokinetic simulation analysis of less frequent nivolumab and pembrolizumab dosing: pharmacoeconomic rationale for dose deescalation. *J Clin Pharmacol*. 2022;62(4):532-540. doi:10.1002/jcph.1984
 139. FDA. Clinical pharmacology and biopharmaceutic review (nivolumab). Application Number 125554Orig1s000. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000ClinPharmR.pdf.
 140. Zhang J, Sanghavi K, Shen J, et al. Population pharmacokinetics of nivolumab in combination with ipilimumab in patients with advanced malignancies. *CPT Pharmacomet Syst Pharmacol*. 2019;8(12):962-970. doi:10.1002/psp4.12476
 141. FDA-AACR public workshop on optimizing dosages for oncology drug products: quantitative approaches to select dosages for clinical trials. <https://www.aacr.org/professionals/policy-and-advocacy/regulatory-science-and-policy/events/fda-aacr-workshop-optimizing-dosages-for-oncology-drug-products/>
 142. Sheiner LB. Learning versus confirming in clinical drug development. *Clin Pharmacol Ther*. 1997;61(3):275-291. doi:10.1016/S0009-9236(97)90160-0
 143. Di Gion P, Kanefendt F, Lindauer A, et al. Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. *Clin Pharmacokinet*. 2011;50(9):551-603. doi:10.2165/11593320-000000000-00000
 144. de Wit D, Guchelaar HJ, den Hartigh J, Gelderblom H, van Erp NP. Individualized dosing of tyrosine kinase inhibitors: are we there yet? *Drug Discovery Today*. 2015;20(1):18-36. doi:10.1016/j.drudis.2014.09.007
 145. Tringale KR, Carroll KT, Zakeri K, Sacco AG, Barnachea L, Murphy JD. Cost-effectiveness analysis of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck. *J Natl Cancer Inst*. 2018;110(5):479-485. doi:10.1093/jnci/djx226
 146. Hirsch I, Goldstein DA, Tannock IF, Butler MO, Gilbert DC. Optimizing the dose and schedule of immune checkpoint inhibitors in cancer to allow global access. *Nat Med*. 2022;28(11):2236-2237. doi:10.1038/s41591-022-02029-1
 147. Chen YH, Wang CC, Chen YY, Wang JH, Hung CH, Kuo YH. Low-dose nivolumab in advanced hepatocellular carcinoma. *BMC Cancer*. 2022;22(1):1153. doi:10.1186/s12885-022-10271-6
 148. Rossi E, Bersanelli M, Gelibter AJ, et al. Combination therapy in renal cell carcinoma: the best choice for every patient? *Curr Oncol Rep*. 2021;23(12):147. doi:10.1007/s11912-021-01140-9
 149. Zhou L, Reddy MB, Mittapalli RK, Yang J, Yin D. Oncology combination dose-finding study design for targeted and immuno-oncology therapies. *Clin Pharmacol Ther*. 2024;115(1):29-35. doi:10.1002/cpt.3085
 150. Venkatakrishnan K, Jayachandran P, Seo SK, van der Graaf PH, Wagner JA, Gupta N. Moving the needle for oncology dose optimization: A call for action. *CPT: Pharmacomet Syst Pharmacol*. 2024;13(6):909-918. doi:10.1002/psp4.13157
 151. Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important? *BMJ*. 1998;316(7126):201. doi:10.1136/bmj.316.7126.201
 152. Bi Y, Liu J, Li F, et al. Model-informed drug development in pediatric dose selection. *J Clin Pharmacol*. 2021;61(S1):S60-S69. doi:10.1002/jcph.1848
 153. FDA. Pharmacokinetic-based criteria for supporting alternative dosing regimens of programmed cell death receptor-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) blocking antibodies for treatment of patients with cancer: guidance for industry. 2023. Accessed May 1, 2023. <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/pharmacokinetic-based-criteria-supporting-alternative-dosing-regimens-programmed-cell-death-receptor>
 154. ter Heine R, van den Heuvel MM, Piet B, et al. A systematic evaluation of cost-saving dosing regimens for therapeutic antibodies and antibody-drug conjugates for the treatment of lung cancer. *Targeted Oncol*. 2023;18(3):441-450. doi:10.1007/s11523-023-00958-6
 155. Tang M, Pearson SA, Simes RJ, Chua BH. Harnessing real-world evidence to advance cancer research. *Current Oncol*. 2023;30(2):1844-1859. doi:10.3390/curroncol30020143

Supplemental Information

Additional supplemental information can be found by clicking the Supplements link in the PDF toolbar or the Supplemental Information section at the end of web-based version of this article.